NCIt definition : The tosylate salt form of talazoparib, an orally bioavailable inhibitor of the nuclear
enzyme poly(ADP-ribose) polymerase (PARP) with potential antineoplastic activity.
Upon administration, talazoparib selectively binds to PARP and prevents PARP-mediated
DNA repair of single strand DNA breaks via the base-excision repair pathway. This
enhances the accumulation of DNA strand breaks, promotes genomic instability and eventually
leads to apoptosis. PARP catalyzes post-translational ADP-ribosylation of nuclear
proteins that signal and recruit other proteins to repair damaged DNA and is activated
by single-strand DNA breaks.;
UNII : 02WK9U5NZC;
InChIKey : QUQKKHBYEFLEHK-QNBGGDODSA-N;
CAS number : 1373431-65-2; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1373431-65-2
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
https://ansm.sante.fr/actualites/avis-de-lansm-du-20-11-2023-sur-le-medicament-talzenna-dans-le-cadre-dune-demande-daap 2023 false false false France French drug information talazoparib Talazoparib Tosylate prostatic neoplasms, Castration-Resistant metastatic castration resistant prostate cancer talazoparib